T40
Latest content
- Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic
- Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo
- Copenhagen Airports A/S, SAS Cargo and World Courier to host FlyPharma 2026
- Gilead to acquire Arcellx in deal worth $7.8bn
- PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis
Latest intelligence
- Communication breakdown
- Medicine shortages strike again – can radio-frequency identification technology help?
- Pandemic readiness is now a financial risk test – and the UK must treat it that way
- Designing healthcare AI that works for every patient
- Oral health and systemic disease: why they may be more closely linked than we thought